Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Jan;29(1):115-117.
doi: 10.1016/j.cmi.2022.09.020. Epub 2022 Oct 4.

Remdesivir for the treatment of COVID-19: author's response

Todd C Lee  1 , Emily G McDonald  2
Affiliations
Comment

Remdesivir for the treatment of COVID-19: author's response

Todd C Lee et al. Clin Microbiol Infect. 2023 Jan.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Random-effects meta-analysis stratified by oxygenation requirements. ACTT, Adaptive Covid-19 Treatment Trial; CATCO, Canadian Treatments for COVID-19. ∗Excludes patients already reported in the Solidarity 1 (NEJM 2020) and CATCO (CMAJ 2022) trials. ∗∗Excludes patients reported in the Solidarity 1 (NEJM 2022) trial.
Fig. 2
Fig. 2
Probability density functions for combined posterior distributions of the included remdesivir trials in patients requiring supplemental oxygen without mechanical ventilation. AUC, area under the curve.
See this image and copyright information in PMC

Comment on

References

    1. Lee T.C., Senecal J., Hsu J.M., McDonald E.G. Ongoing citations of a retracted study involving cardiovascular disease, drug therapy, and mortality in COVID-19. JAMA Intern Med. 2021;181:1535–1537. doi: 10.1001/jamainternmed.2021.4112. - DOI - PMC - PubMed
    1. Lee T.C., Murthy S., Corpo O.D., Senécal J., Butler-Laporte G., Sohani Z.N., et al. Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis. Clin Microbiol Infect. 2022;28:1203–1210. doi: 10.1016/j.cmi.2022.04.018. - DOI - PMC - PubMed
    1. WHO Solidarity Trial Consortium Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet. 2022;399:1941–1953. doi: 10.1016/S0140-6736(22)00519-0. - DOI - PMC - PubMed